查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570835

炭疽治療藥物市場：按治療類型、給藥途徑、患者類型、最終用戶、治療持續時間、作用機制、疾病形式 - 全球預測 2025-2030

Anthrax Treatment Market by Treatment Type (Antibiotics, Antitoxins, Combined Therapy), Route Of Administration (Inhalational, Intravenous, Oral), Patient Type, End-User, Therapy Duration, Mechanism Of Action, Disease Form - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年炭疽治療藥物市場價值為3.8945億美元，預計到2024年將達到4.1566億美元，複合年成長率為7.75%，到2030年將達到6.5688億美元。

炭疽藥物是製藥和醫療產業的重要組成部分，專注於控制和根除炭疽菌感染。這個市場包括各種醫療干預措施，包括Ciprofloxacin和多西環素等抗生素、新開發的抗蛇毒血清以及用於先發製人免疫和暴露後預防的疫苗。由於病原體有可能被用於生物恐怖主義，因此對有效的炭疽治療需求更加迫切，需要強力的準備和快速反應能力。應用主要超越醫療環境，涵蓋軍事、農業和公共衛生領域，凸顯了對綜合干預策略和產品的需求。炭疽治療藥物市場的關鍵成長要素包括政府增加對生物防禦措施的資助、在生物恐怖主義威脅後加強公共衛生宣傳活動以及提高治療方案有效性的生物技術研究的進步。速效、頻譜治療的創新以及減少副作用和延長免疫力的疫苗配方的開發存在潛在的機會。生物技術公司、學術機構和政府機構之間的合作將為創新提供肥沃的土壤，確保與動態監管標準保持一致，並利用人工智慧等技術進行快速藥物開發。然而，市場成長面臨高昂的研發成本、監管核准的複雜性以及炭疽菌自然爆發的罕見性等挑戰，限制了重大投資的理由。此外，大眾對疫苗相關副作用的擔憂也是另一個障礙。最具創新潛力的領域包括開發對抗抗生素抗藥性的雙效療法、新型疫苗輸送系統以及用於快速發現和開始治療的改進診斷工具。市場本質上是由必要性和緊急準備驅動的，而對研究和策略夥伴關係關係的關注對於在這些挑戰中推動永續成長至關重要。

主要市場統計
基準年[2023] 38945萬美元
預測年份 [2024] 41566萬美元
預測年份 [2030] 65688萬美元
複合年成長率（%） 7.75%

市場動態：揭示快速發展的炭疽藥物市場的關鍵市場洞察

供需的動態交互作用正在改變炭疽藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助組織降低政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特的五力：駕馭炭疽藥物市場的策略工具

波特的五力架構是了解炭疽治療藥物市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解炭疽藥物市場的外部影響

外部宏觀環境因素在塑造炭疽治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解炭疽藥物市場的競爭狀況

對炭疽治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣炭疽治療市場供應商的績效評估

FPNV定位矩陣是評估炭疽治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃炭疽治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對炭疽治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大以感染疾病治療為重點的生物技術和製藥業
      • 人們越來越需要有效、快速起效的治療方法來控制炭疽症狀。
      • 加強發展中地區的衛生基礎設施以管理感染疾病爆發
      • 用於開發炭疽菌疫苗和治療方法的公共和私人資金
    • 抑制因素
      • 發展中地區的認知和醫療基礎設施有限限制了炭疽藥物的市場滲透。
      • 維持疫苗分銷低溫運輸物流的挑戰 炭疽治療市場
    • 機會
      • 對先進生物恐怖主義對策和緊急應變準備的需求不斷增加
      • 將人工智慧融入標靶炭疽藥物解決方案的開發
      • 改善醫療基礎設施，使發展中地區獲得有效的炭疽菌治療
    • 任務
      • 新興市場的炭疽菌意識和診斷能力有限，影響了治療效果
      • 供應鏈中斷影響炭疽治療方案的可用性和可近性
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章炭疽治療藥物市場：依治療類型

  • 介紹
  • 抗生素
    • Ciprofloxacin
    • 強力黴素
    • levofloxacin
    • 青黴素
  • 抗毒素
    • 奧比妥沙昔單抗
    • 拉西巴庫單抗
  • 聯合治療
    • 抗生素和抗毒素

第7章炭疽治療市場：依給藥途徑

  • 介紹
  • 吸入
  • 靜脈
  • 口服
  • 皮下的

第8章炭疽治療藥物市場：依患者類型

  • 介紹
  • 成人
  • 老年人
  • 兒科的

第9章炭疽治療藥物市場：依最終使用者分類

  • 介紹
  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院

第10章炭疽治療藥物市場：依治療持續時間

  • 介紹
  • 長期治療
    • 4週或以上
  • 短期治療
    • 2-4週
    • 2週或更短時間

第11章炭疽藥物市場：按作用機制

  • 介紹
  • 殺菌作用
  • 細菌停滯

第12章炭疽治療市場：依疾病類型

  • 介紹
  • 皮膚炭疽病
  • 胃腸道炭疽
  • 吸入性炭疽
  • 注射炭疽菌

第13章美洲炭疽藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太炭疽藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章 歐洲、中東和非洲炭疽藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0102

The Anthrax Treatment Market was valued at USD 389.45 million in 2023, expected to reach USD 415.66 million in 2024, and is projected to grow at a CAGR of 7.75%, to USD 656.88 million by 2030.

Anthrax treatment is a critical segment within the pharmaceutical and healthcare industries, concentrating on the management and eradication of Bacillus anthracis infections. This market's scope encompasses various medical interventions, including antibiotics like ciprofloxacin, doxycycline, and newly developed antitoxins and vaccines aimed at preemptive immunization and post-exposure prophylaxis. The necessity for effective anthrax treatment is heightened due to the potential use of the pathogen in bioterrorism, demanding robust preparedness and rapid response capabilities. Applications chiefly transcend healthcare settings, encompassing military, agricultural, and public health domains, highlighting the need for comprehensive intervention strategies and products. Key growth influencers in the anthrax treatment market include increased government funding for biodefense measures, heightened public health campaigns post-bioterror threats, and advancements in biotechnological research enhancing the efficacy of treatment options. Potential opportunities lie in innovating fast-acting, broad-spectrum therapeutics and developing vaccine formulations that offer prolonged immunity with reduced side-effects. Encouragingly, collaborations among biotech firms, academia, and governmental bodies present a fertile ground for innovation, ensuring alignment with dynamic regulatory standards and leveraging technological advancements like AI for rapid drug development. However, market growth is challenged by factors such as the high cost of R&D, complexities associated with regulatory approvals, and the rarity of natural anthrax occurrences, which constrain the justification for substantial investment. Furthermore, public apprehensions regarding vaccine-related adverse effects pose additional hurdles. The most promising areas for innovation include the development of dual-action therapeutics that address antibiotic resistance, novel vaccine delivery systems, and improved diagnostic tools for rapid detection and treatment initiation. The market is inherently driven by necessity and emergency preparedness, with its focus on research and strategic partnerships being quintessential to facilitate sustainable growth amidst these challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 389.45 million
Estimated Year [2024] USD 415.66 million
Forecast Year [2030] USD 656.88 million
CAGR (%) 7.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anthrax Treatment Market

The Anthrax Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of biotechnology and pharmaceutical industries focusing on infectious disease treatments
    • Growing demand for effective and fast-acting treatments to manage anthrax symptoms
    • Enhanced healthcare infrastructure in developing regions to manage infectious disease outbreaks
    • Public and private funding for the development of vaccines and treatments for anthrax
  • Market Restraints
    • Limited awareness and healthcare infrastructure in developing regions restricts market penetration for anthrax treatment
    • Challenges in maintaining cold chain logistics for vaccine distribution in the anthrax treatment market
  • Market Opportunities
    • Rising demand for advanced bioterrorism countermeasures and emergency response preparedness
    • Integration of artificial intelligence in developing targeted anthrax treatment solutions
    • Improvement in healthcare infrastructure enabling access to effective anthrax treatments in developing regions
  • Market Challenges
    • Limited awareness and diagnosis capabilities for anthrax in emerging markets impacting treatment efficacy
    • Supply chain disruptions affecting the availability and accessibility of anthrax treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Anthrax Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anthrax Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anthrax Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anthrax Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anthrax Treatment Market

A detailed market share analysis in the Anthrax Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anthrax Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anthrax Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anthrax Treatment Market

A strategic analysis of the Anthrax Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anthrax Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Altimmune, AstraZeneca, Bayer HealthCare, Cipla, Elusys Therapeutics, Emergent BioSolutions, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Mylan, Novartis, Paratek Pharmaceuticals, Pfizer, PharmAthene, Roche, Sanofi, and Teva Pharmaceutical Industries.

Market Segmentation & Coverage

This research report categorizes the Anthrax Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antibiotics, Antitoxins, and Combined Therapy. The Antibiotics is further studied across Ciprofloxacin, Doxycycline, Levofloxacin, and Penicillin. The Antitoxins is further studied across Obiltoxaximab and Raxibacumab. The Combined Therapy is further studied across Antibiotics And Antitoxins.
  • Based on Route Of Administration, market is studied across Inhalational, Intravenous, Oral, and Subcutaneous.
  • Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Clinics, Homecare Settings, and Hospitals.
  • Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy. The Long-Term Therapy is further studied across More Than 4 Weeks. The Short-Term Therapy is further studied across 2 To 4 Weeks and Less Than 2 Weeks.
  • Based on Mechanism Of Action, market is studied across Bactericidal and Bacteriostatic.
  • Based on Disease Form, market is studied across Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax, and Injection Anthrax.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of biotechnology and pharmaceutical industries focusing on infectious disease treatments
      • 5.1.1.2. Growing demand for effective and fast-acting treatments to manage anthrax symptoms
      • 5.1.1.3. Enhanced healthcare infrastructure in developing regions to manage infectious disease outbreaks
      • 5.1.1.4. Public and private funding for the development of vaccines and treatments for anthrax
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and healthcare infrastructure in developing regions restricts market penetration for anthrax treatment
      • 5.1.2.2. Challenges in maintaining cold chain logistics for vaccine distribution in the anthrax treatment market
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for advanced bioterrorism countermeasures and emergency response preparedness
      • 5.1.3.2. Integration of artificial intelligence in developing targeted anthrax treatment solutions
      • 5.1.3.3. Improvement in healthcare infrastructure enabling access to effective anthrax treatments in developing regions
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and diagnosis capabilities for anthrax in emerging markets impacting treatment efficacy
      • 5.1.4.2. Supply chain disruptions affecting the availability and accessibility of anthrax treatment options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anthrax Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antibiotics
    • 6.2.1. Ciprofloxacin
    • 6.2.2. Doxycycline
    • 6.2.3. Levofloxacin
    • 6.2.4. Penicillin
  • 6.3. Antitoxins
    • 6.3.1. Obiltoxaximab
    • 6.3.2. Raxibacumab
  • 6.4. Combined Therapy
    • 6.4.1. Antibiotics And Antitoxins

7. Anthrax Treatment Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Inhalational
  • 7.3. Intravenous
  • 7.4. Oral
  • 7.5. Subcutaneous

8. Anthrax Treatment Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Anthrax Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Clinics
  • 9.4. Homecare Settings
  • 9.5. Hospitals

10. Anthrax Treatment Market, by Therapy Duration

  • 10.1. Introduction
  • 10.2. Long-Term Therapy
    • 10.2.1. More Than 4 Weeks
  • 10.3. Short-Term Therapy
    • 10.3.1. 2 To 4 Weeks
    • 10.3.2. Less Than 2 Weeks

11. Anthrax Treatment Market, by Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Bactericidal
  • 11.3. Bacteriostatic

12. Anthrax Treatment Market, by Disease Form

  • 12.1. Introduction
  • 12.2. Cutaneous Anthrax
  • 12.3. Gastrointestinal Anthrax
  • 12.4. Inhalation Anthrax
  • 12.5. Injection Anthrax

13. Americas Anthrax Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Anthrax Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Anthrax Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Altimmune
  • 3. AstraZeneca
  • 4. Bayer HealthCare
  • 5. Cipla
  • 6. Elusys Therapeutics
  • 7. Emergent BioSolutions
  • 8. Gilead Sciences
  • 9. GlaxoSmithKline
  • 10. Johnson & Johnson
  • 11. Lupin Pharmaceuticals
  • 12. Merck & Co.
  • 13. Mylan
  • 14. Novartis
  • 15. Paratek Pharmaceuticals
  • 16. Pfizer
  • 17. PharmAthene
  • 18. Roche
  • 19. Sanofi
  • 20. Teva Pharmaceutical Industries

LIST OF FIGURES

  • FIGURE 1. ANTHRAX TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ANTHRAX TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ANTHRAX TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ANTHRAX TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTHRAX TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTHRAX TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY OBILTOXAXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RAXIBACUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS AND ANTITOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INHALATIONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MORE THAN 4 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY 2 TO 4 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY LESS THAN 2 WEEKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY BACTERICIDAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY BACTERIOSTATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CUTANEOUS ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GASTROINTESTINAL ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INHALATION ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INJECTION ANTHRAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY COMBINED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ANTHRAX TREATMENT MARKET SIZE, BY DISEASE FORM, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 345. GERMANY ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXINS, 2018-2030 (USD MI